Introducing MIRCERA
MIRCERA is a novel continuous erythropoietin receptor activator indicated for the treatment of anaemia associated with chronic kidney disease in patients on dialysis and patients not on dialysis. It is structurally different to other erythropoiesis-stimulating agents and provides stable and sustained haemoglobin levels with once-monthly maintenance dosing for all CKD patients currently treated with an ESA*.
This section aims to provide essential information about MIRCERA, including its features and benefits, mode of action.
* not approved for use in children or adolescents below 18 years of age